Copyright © 2022 StrategyHelix Inc. All Rights Reserved.
Global Cell Therapy Biomanufacturing Market 2022
Cell therapies aims to introduce new, healthy cells into a patient’s body, to replace the diseased or missing ones. Manufacturing them involves collecting a specific set of cells from the blood, modifying them to produce a more vigorous attack on a patient’s cancer cells, and then reinjecting them into the patient. The global cell therapy biomanufacturing market is set to increase by US$ 4.4 billion from 2022 to 2028, representing a compound annual growth rate (CAGR) of 8.8% during the forecast period.
The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for cell therapy biomanufacturing. The global cell therapy biomanufacturing market is segmented on the basis of application, and region. On the basis of application, the global cell therapy biomanufacturing market has been segmented into bone repair, cancer, cardiovascular diseases, neurological disorders, skeletal muscle repair, others. Among these, the skeletal muscle repair segment was accounted for the highest revenue generator in 2021. In terms of geography, the global cell therapy biomanufacturing market has been segmented into Asia Pacific, Europe, North America, MEA (Middle East and Africa), Latin America. North America is estimated to account for the largest share of the global cell therapy biomanufacturing market.
The global cell therapy biomanufacturing market is highly competitive. As of 2021, the major players in the global cell therapy biomanufacturing market were Bone Therapeutics S.A., Caladrius Biosciences Inc., Iovance Biotherapeutics Inc., Lonza Group AG, Merck KGaA, Novartis AG, Regen BioPharma Inc., Regeneus Ltd., The Bristol-Myers Squibb Company (BMS).
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the cell therapy biomanufacturing market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Application: bone repair, cancer, cardiovascular diseases, neurological disorders, skeletal muscle repair, others
Region: Asia Pacific, Europe, North America, MEA (Middle East and Africa), Latin America
Years considered: this report covers the period 2018 to 2028
Key Benefits for Stakeholders
– Get a comprehensive picture of the global cell therapy biomanufacturing market
– Pinpoint growth sectors and trends for investment
Table of Contents
Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Cell therapy biomanufacturing market overview
Part 3. Market breakdown by application
– Bone repair
– Cardiovascular diseases
– Neurological disorders
– Skeletal muscle repair
Part 4. Market breakdown by region
– Asia Pacific
– North America
– MEA (Middle East and Africa)
– Latin America
Part 5. Key companies
– Bone Therapeutics S.A.
– Caladrius Biosciences, Inc.
– Iovance Biotherapeutics, Inc.
– Lonza Group AG
– Merck KGaA
– Novartis AG
– Regen BioPharma, Inc.
– Regeneus Ltd.
– The Bristol-Myers Squibb Company (BMS)